"Immunogenicity, tolerance and reactogenicity of Quimi-Hib and alum phospate adjuvanted Quimi-Hib vaccines in healthy infants according to 6 - 10 - 14 weeks primary vaccination series. A multicenter, controlled, randomized, doubled blind clinical trial."

Trial Profile

"Immunogenicity, tolerance and reactogenicity of Quimi-Hib and alum phospate adjuvanted Quimi-Hib vaccines in healthy infants according to 6 - 10 - 14 weeks primary vaccination series. A multicenter, controlled, randomized, doubled blind clinical trial."

Planning
Phase of Trial: Phase II

Latest Information Update: 07 Sep 2016

At a glance

  • Drugs Hib vaccine conjugate (Primary) ; Aluminium phosphate
  • Indications Haemophilus infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Sep 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top